Provided herein are novel heteroaromatic substituted cyclopropanes of the Formula (I): ##STR00001## as well as compositions, including pharmaceutical compositions, containing the same, and the use thereof in the treatment of various neurological and psychological disorders, e.g., anxiety and depression, treatable by antagonizing CRF receptors.